Picture of Shionogi & Co logo

4507 Shionogi & Co Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareConservativeLarge CapSuper Stock

Momentum

Relative Strength (%)
1m+9.93%
3m+17.35%
6m+24.99%
1yr+6.35%
Volume Change (%)
10d/3m-13.64%
Price vs... (%)
52w High-5.71%
50d MA+5.12%
200d MA+9.58%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)12.16
PEG Ratio (f)n/a
EPS Growth (f)-2.04%
Dividend Yield (f)2.55%
Valuation (ttm)IndustryMarket
Price to Book Value1.52
Price to Tang. Book1.73
Price to Free Cashflow13.06
Price to Sales4.74
EV to EBITDA9.09

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital10.21%
Return on Equity13.29%
Operating Margin33.3%

Financial Summary

Year End 31st MarUnit202020212022202320242025E2026ECAGR / Avg
Total Revenue¥m333,371297,177335,138426,684435,081450,771457,6783.41%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-19.04-5.8+3.11+71.17-5.54-1.34-2.04n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202531st Mar 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Shionogi & Co EPS forecast chart

Profile Summary

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

Directors

Last Annual
March 31st, 2024
Last Interim
December 31st, 2024
Incorporated
June 5th, 1919
Public Since
May 16th, 1949
No. of Shareholders
56,112
No. of Employees
4,959
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
jp flag iconTokyo Stock Exchange
Shares in Issue
850,685,601

4507 Share Price Performance

Upcoming Events for 4507

Full Year 2025 Shionogi & Co Ltd Earnings Release

Shionogi & Co Ltd Annual Shareholders Meeting

Q1 2026 Shionogi & Co Ltd Earnings Release

Q2 2026 Shionogi & Co Ltd Earnings Release

Similar to 4507

Picture of Astellas Pharma logo

Astellas Pharma

jp flag iconTokyo Stock Exchange

Picture of Astena Holdings Co logo

Astena Holdings Co

jp flag iconTokyo Stock Exchange

Picture of CanBas Co logo

CanBas Co

jp flag iconTokyo Stock Exchange

Picture of CellSeed logo

CellSeed

jp flag iconTokyo Stock Exchange

FAQ